Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2011 / Article

Research Article | Open Access

Volume 2011 |Article ID 462525 | https://doi.org/10.1155/2011/462525

Young Jin Moon, Daniel A. Brazeau, Marilyn E. Morris, "Dietary Phenethyl Isothiocyanate Alters Gene Expression in Human Breast Cancer Cells", Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 462525, 8 pages, 2011. https://doi.org/10.1155/2011/462525

Dietary Phenethyl Isothiocyanate Alters Gene Expression in Human Breast Cancer Cells

Received04 Jun 2009
Revised05 Nov 2009
Accepted31 Aug 2010
Published28 Sep 2010


Phenethyl isothiocyanate (PEITC), a component in cruciferous vegetables, can block chemical carcinogenesis in animal models. Our objective was to determine the effect of treatment with PEITC on gene expression changes in MCF-7 human breast cancer cells in order to evaluate potential mechanisms involved in its chemopreventive effects. MCF-7 cells were treated for 48 hours with either PEITC (3  M) or the vehicle. Total RNA was extracted from cell membrane preparations, and labeled cDNA's representing the mRNA pool were reverse-transcribed directly from total RNA isolated for use in the microarray hybridizations. Two specific human GE Array Kits (Superarray Inc.) that both contain 23 marker genes, related to signal transduction pathways or cancer/tumor suppression, plus 2 housekeeping genes ( -actin and GAPDH), were utilized. Arrays from treated and control cells ( per group) were evaluated using a Student's t-test. Gene expression was significantly induced for tumor protein p53 (p53), cyclin-dependent kinase inhibitor 1C (p57 Kip2), breast cancer Type 2 early onset (BRCA2), cAMP responsive element binding protein 2 (ATF-2), interleukin 2 (IL-2), heat shock 27 KD protein (hsp27), and CYP19 (aromatase). Induction of p57 Kip2, p53, BRCA2, IL-2, and ATF-2 would be expected to decrease cellular proliferation and increase tumor suppression and/or apoptosis. PEITC treatment produced significant alterations in some genes involved in tumor suppression and cellular proliferation/apoptosis that may be important in explaining the chemopreventive effects of PEITC.

1. Introduction

Diet and environmental factors may represent very significant factors in the genesis of breast cancer. Organic isothiocyanates (ITCs, R-N=C=S), also known as mustard oils, are present in the form of glucosinolates in Brassica and other vegetables of the family Cruciferae (e.g., cabbage, cauliflower, brussels sprouts, watercress, and broccoli, kale) and the genus Raphanus (radishes and daikons) [1]. When vegetables are ingested, ITCs are liberated through the hydrolysis of glucosinolates either by myrosinase that is released when vegetables are chewed, or by microflora in the intestinal tract [1, 2]. The human intake of glucosinolates, the biological precursors of ITCs, can be as high as 300 mg/day (660  mol/day) and tens of milligrams of ITCs are released following the consumption of vegetables in the diet [3]. Additionally, dietary supplements containing ITCs or extracts of cruciferous vegetables, such as Cruciferous Plus and Broccoli Sprouts, are marketed for their health promotion properties.

More than 20 natural and synthetic ITCs have been shown to block chemical carcinogenesis induced by environmental carcinogens including polycyclic aromatic hydrocarbons and nitrosamines in animal models [36]. It has been reported that urinary ITC levels are significantly associated with reduced breast cancer risk in pre- and postmenopausal women [7]. One study demonstrated that Brassica vegetable consumption increases the ratio of 2-hydroxyestrone (a noncarcinogenic metabolite of estrogen) to 16α-hydroxyestrone (a carcinogenic metabolite of estrogen), in healthy postmenopausal women [8]. The mechanisms underlying the chemopreventive effects of ITCs are likely diverse and multi-factorial and remain largely unknown at this time.

Phenethyl isothiocyanate (PEITC, Figure 1) is one of the most extensively studied ITCs; it has been reported to have effective chemopreventive activity for a wide variety of tumors, and no apparent toxicity has been observed in animal models [9]. PEITC can inhibit Phase I enzymes, including the various cytochrome P450 enzymes that are responsible for the conversion of procarcinogens to highly reactive electrophilic carcinogens that can form DNA adducts; PEITC can also induce Phase II enzymes, including glutathione S-transferase and quinone reductase, that inactivate carcinogens and promote their excretion [10, 11]. More recently, it has been found that PEITC could induce cell cycle arrest and apoptotic cell death [1217]. The value of PEITC for inhibition of cell growth of human breast cancer MCF-7 cells (evaluated over a 48-h period) is 6.51 0.86  M [16]. Interestingly, PEITC acts more potently than the pure antiestrogen ICI 182,780 (Fulvestrant; Faslodex) to inhibit the growth of estrogen receptor positive breast cancer MCF-7 and H3396 cells and ER-negative MDA-MB-231 and SK-BR-3 cells [17]. In addition, PEITC, but not ICI 182,780, can downregulate the steady state levels of ER- 36 protein (36 kDa variant of the ER- , which mediates membrane-initiated estrogen and antiestrogen signaling) in breast cancer cells [17]. The exact mechanism underlying the effect of PEITC on the ER- 36 protein is unknown [17]. PEITC is known to selectively kill cancer cells, but not normal cells, by generating reactive oxygen species (ROS) to trigger signal transduction, resulting in cell cycle arrest and/or apoptosis [18]. PEITC is also an effective inhibitor of hypoxia inducible factor (HIF), a transcription factor that plays an important role in the expression of proangiogenic factors [19].

To better understand the precise molecular mechanism(s) by which PEITC exerts its effects on MCF-7 human breast cancer cells, we utilized cDNA gene arrays to assess the gene expression profiles of breast cancer cells treated with physiologically relevant levels (3  M) of PEITC. Studies have examined the mechanisms underlying the cell growth inhibitory effects of PEITC in human leukemia [20], lung cancer [21], HeLa cervical cancer [22], HT-29 colon adenocarcinoma [15], pancreatic cancer [23], and human prostate cancer PC-3 [24] cells. However, few studies have used breast cancer cells for investigating the effect of PEITC on gene expression. In the present study, genes involved in cell cycle pathways, apoptosis, and metastasis, important for chemoprevention, were evaluated by gene-array expression technology.

2. Methods

2.1. Materials

PEITC and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). RPMI 1640 medium, fetal bovine serum, and PBS were from Invitrogen (Carlsbad, CA). MCF-7 cells were obtained from the National Cancer Institute.

2.2. Cell Culture

MCF-7 cells were grown in 75 cm2 cell culture flasks in RPMI 1640 culture media supplemented with 10% FBS, 100 units/ml penicillin and 100  g/ml of streptomycin, in a 37°C incubator in a humidified atmosphere of 5% CO2/95% air. MCF-7 cells, with passage numbers of 16 to 24, were used in the experiments. Cells were treated with either 3  M PEITC or 0.015% DMSO (vehicle control) for 48 h. The rationale for choosing this time point was to capture gene expression profiles of genes involved during the onset of growth inhibition and apoptotic processes. The concentration of PEITC used is one that is achievable in plasma after the consumption of food or dietary supplements. Plasma concentration of up to 1  M has been reported after the ingestion of watercress 100 g [25].

2.3. Total RNA Isolation

Total RNA from each sample was isolated using a SV Total RNA Isolation System (Promega, Cat.#Z3100), following the manufacturer’s instructions. Total RNA was quantitated spectrophotometrically at 260 nm.

2.4. Gene Array

Two specific human GEArray Kits (SuperArray Inc., Frederick, MD, signal transduction pathway array and cancer/tumor suppressor array), were utilized. Each array consists of 23 genes in duplicate, as well as control spots (PUC18 as negative control; actin and glyceraldehyde-3-phosphate dehydrogenase (G3PDH)) (Table 1). The gene arrays were used according to the manufacturer's instructions. In brief, using the reagents provided (i.e., 5X GEAlabeling Buffer, RNase-free water, RT Primer, RNase Inhibitor, and the array-specific reagent), gene specific cDNAs were prepared and labeled from total RNA by reverse transcription with MMLV reverse transcriptase (Invitrogen, Carlsbad, CA) and chemiluminescence-labeled biotin dUTP (Invitrogen, Carlsbad, CA). Relative expression levels of each gene were analyzed using a Kodak Image Station 440CF. actin was used for normalization. Each experiment was repeated four times.

(a) Cancer/tumor suppressor array

APCAdenomatosis polyposis coli
BRCA1Breast cancer 1, early onset
BRCA2Breast cancer 2, early onset
CBPHuman CREB-binding protein
DPC4Human homozygous deletion target in pancreatic carcinoma (DPC4)
IRF-1Interferon regulatory factor 1
MSH2mutS (E. coli) homolog 2 (colon cancer, nonpolyposis type 1)
NF2Neurofibromin 2 (bilateral acoustic neuroma)
p18 (cdk4 inhibitor)Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
p19Ink4dCyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
p21Waf1 (p21Cip1)Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
p27Kip1Cyclin-dependent kinase inhibitor 1B (p27, Kip1)
p300CREB-binding protein
p53Tumor protein p53 (Li-Fraumeni syndrome)
p57Kip2Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
PTENPhosphatase and tensin homolog (mutated in multiple advanced cancers 1
RbRetinoblastoma 1 (including osteosarcoma)
TGFbR1 (ALK-5)Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kD)
TGFbR2Transforming growth factor, beta receptor II (70–80 kD)
TSC-1Tuberous sclerosis 1
TSC-2Tuberous sclerosis 2
VHLVon Hippel-Lindau syndrome
WT1Wilms tumor 1

(b) Signal transduction pathway array

ATF-2 (creb-2)cAMP responsive element binding protein 2
baxBCL2-associated X protein
CD5T-cell surface glycoprotein CD5
c-fosHuman cellular oncogene c-fos
c-mycv-myc avian myelocytomatosis viral oncogene homolog
CYP19 (aromatase p450) (p450XIX)cytochrome P450, subfamily XIX (aromatization of androgens)
egr-1Early growth response 1
Fas (Apo-1) (CD95)Tumor necrosis factor receptor superfamily, member 6
gadd45DNA-damage-inducible transcript 1
hsf1 (tcf5)HSF1 (TCF5, Heat shock factor protein)
hsp27 (hsp b1)Heat shock 27 KD protein
hsp90 (CDw52)Hsp90 (Human mRNA for 90-kDa heat-shock protein)
IκB (mad3)Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
IL-2Interleukin 2
iNOSInducible nitric oxide synthase (NOS)
mdm2Mouse double minute 2, human homolog of; p53-binding protein
NFκBNuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
( )Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
p53Tumor protein p53 (Li-Fraumeni syndrome)
Cyclin-dependent kinase inhibitor 1C (p57, Kip2)
pig7LPS-induced TNF-alpha factor
pig8etoposide-induced mRNA

2.5. Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction (RTQ RT-PCR)

Real-time quantitative reverse transcriptase polymerase chain reaction was performed on actin (for normalization) and CYP19 using Stratagene’s Mx4000 Multiplex Quantitative PCR System (Stratagene, La Jolla, CA). The same total RNA prepared for the gene arrays was also used for RTQ RT-PCR. Total RNA (560 ng) from each sample was reverse transcribed into cDNA using a Superscript first strand cDNA synthesis kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. PCR reactions for CYP19 and actin were carried out by mixing 5  L of cDNA, 5  L of 10 PCR buffer, 2  L of deoxynucleoside triphosphate mix (5 mM each dATP, dCTP, dGTP, and dTTP), 1  L each of 10  M primer, 0.5  L reference dye rhodamine-X (1/500 dilution, Molecular Probes, Eugene, OR), 0.5  L SYBR green I (1/750 dilution, Molecular Probes, Eugene, Or), 2 U Taq polymerase (Eppendorf, Westbury, NY) and 34.75  L H2O, and amplified for 40 cycles. Primers for actin (forward: -CTGGCCGGGACCTGACT- , Reverse: - TCCTTAATGTCACGCACGATTT- , annealing temperature: 57°C) were designed using the computer program Primer Express (Perkin-Elmer Applied Biosystems, Foster City, CA). Primers for CYP19 (Forward: -TGGAAAACAACTCGACCCTTCT- , Reverse: -CACAGACTGTGACCATACGAACAA- ) have been described [26]. The PCR products were resolved by electrophoresis through a 2% agarose gel to confirm target size and the presence of single PCR product.

The PCR product of each gene was cloned into a pCR 2.1 TOPO vector (Invitrogen, Carlsbad, CA) and transformed into One Shot chemically competent Escherichia coli cells (Invitrogen, Carlsbad, CA). Cloned PCR products were confirmed by sequencing and used to construct standard curves for absolute quantification of copy number. The standard curves were run in triplicate concurrently on the same plate with samples, which were also run in triplicate. The reported copy number was estimated from the linear regression of the standard curve on the same plate.

2.6. Statistical Analysis

Student’s -tests with was used for statistical analysis for both arrays and RTQ RT-PCR.

3. Results

Treatment of MCF-7 cells for 48 hours with PEITC (3  M) significantly altered the expression of seven of the 46 genes present on the two arrays: p53, ATF-2, hsp27, BRCA2, IL-2, p57, and CYP19 (Table 2 and Figure 2). All 7 genes were upregulated by ~2- to 5-fold. Alterations in 5 of these genes (p53, ATF2, BRCA2, IL-2, and p57) could be considered to have beneficial effects for cancer prevention. A listing of genes tested using Superarrays (Cancer/Tumor suppressor array and Signal transduction pathway array) can be found in Table 1.

Gene name     DescriptionFold S.D.

p57cyclin-dependent kinase inhibitor 1C5.23* 2.74
CYP19cytochrome P450, subfamily XIX5.22*** 0.988
BRCA2Breast Cancer 2, early-onset4.22* 2.30
IL-2Interleukin-2, T-cell growth factor3.16* 1.22
ATF2Activating Transcription Factor 22.60* 0.900
p53Tumor protein p532.12* 1.46
Hsp27Heat shock 27 KD protein1.84* 0.409

4. Discussion

PEITC increased the expression of p53, a tumor suppressor gene, by 2.12 fold [32]. Tumor suppressor genes encode for proteins whose normal function is to inhibit cell transformation and whose inactivation results in tumor cell growth and survival [32]. Located on chromosome band 17p13, p53 encodes a 53-kd multifunctional transcription factor that regulates the expression of genes involved in cell cycle control, apoptosis, DNA repair, and angiogenesis [32]. Induction of p53 by PEITC at a low concentrations ( 10  M) is consistent with the findings of a publication that reported the effects of PEITC in human nonsmall cell lung carcinoma A549 cells [33]. In these cells, induction of apoptosis occurred at low concentrations of PEITC ( 10  M), and Western blot analyses demonstrated that increased expression of p53 protein was associated with PEITC-induced apoptosis [33]. c-Jun N-terminal kinase (JNK) is involved in PEITC-induced apoptosis, and p53 is known as a substrate of JNK [34]. In contrast, recent immunoblot analyses showed that PEITC 3  M did not increase the protein expression of p53 in MCF-7 cells [35]. However, the shorter incubation times (12, 24, and 36 hours) used in this study may not have been long enough to produce changes in protein expression. The treatment of MCF-7 cells with PEITC (10 or 30  M for 24 or 36 h) suppressed the expression of p53 [35], suggesting that the effect of PEITC on p53 expression may be dose- and time-dependent.

Although we did not investigate the effect of PEITC on p53 activity, it is possible that PEITC also induces p53 activity through GADD34 (Growth Arrest and DNA Damage-Inducible Protein), a proapoptotic gene. In a previous study, 25  M PEITC upregulated expression of GADD34 mRNA [36], and GADD34 is known to induce p53 phosphorylation [37]. In fact, it has recently been reported that PEITC can selectively deplete mutant p53 and restore wild type function to p53 in a variety of tumor cells [38]. In this study, tumor cell lines with mutant p53 became more sensitive to PEITC-induced cytotoxicity than tumor cells with wild type p53, suggesting that the normal p53 checkpoint control pathways have been restored in the mutant p53-expressing tumor cells.

Expression of ATF-2 was increased by PEITC (2.60-fold). ATF-2 is a member of the ATF/CREB family of proteins. It is also known as a cAMP response element-binding protein (CREBP-1). It acts as a transcription factor which regulates transcription in response to the extracellular signals and has a decisive role in cell proliferation, tumorigenesis and apoptosis. Breast cancer frequently develops in mutant mice heterozygous for the ATF-2 gene [39]. Therefore, the ATF-2 gene is considered as a candidate tumor suppressor gene [39]. Changes in gene expression may be mediated through the mitogen-activated protein kinase (MAPK) pathway. PEITC can regulate MAPK—mediated luciferase reporter gene activities [40]. MAPKs can phosphorylate many transcription factors, including c-Jun and ATF-2, and ultimately lead to changes in gene expression [40].

PEITC exposure resulted in the upregulation of Hsp27 by 1.84-fold in MCF-7 cells in this study. The induction of Hsp27 in response to various types of stress correlates with increased resistance to subsequent cellular damage [27]. Hsp27 has also been reported to inhibit apoptosis in NF B and p53 signaling pathways [41]. However, activation of Hsp27 by PEITC may not result in inhibition of apoptosis, as reported for PEITC-treated human hepatoma HepG2 cells [41].

p57 is a tight-binding inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation [42]. Even though information is lacking regarding the effect of PEITC on p57 gene expression, there are several studies which have shown that PEITC can induce other regulators of cell cycle progression at G1, such as p21WAF-1/Cip-1 and p27Kip1, resulting in a cell-cycle arrest in the G1-phase in vascular smooth muscle cells in vitro [43], and prostate cancer cells in xenograft mice [44]. PEITC can also induce G1 cell cycle arrest on HT-29 cells [45]. Mutations of this gene are implicated in sporadic cancers and Beckwith-Wiedemann syndrome, suggesting that this gene is a tumor suppressor candidate [46].

PEITC upregulated BRCA2 by 4.22-fold in the current study. BRCA2 functions as a tumor suppressor gene which stabilizes DNA structures at stalled replication forks [47]. Mutations in BRCA2 have been linked to an elevated risk of breast cancer in young women, which has been demonstrated to be due to the inheritance of dominant susceptibility genes conferring a high risk of breast cancer. An impaired cellular response to DNA damage appears to be a plausible mechanism by which BRCA carriers are at an increased risk of breast cancer [47].

Interleukin-2 (IL-2) was upregulated by PEITC in this investigation. IL-2 is a cytokine produced by T cells whose main function is to stimulate the growth and cytotoxic response of activated T lymphocytes [48]. IL-2 has been used to stimulate the immune system for the treatment of a number of different tumors, including breast cancer [48]. Foa et al. [49] reported that the constitutive secretion of IL-2 by tumor cells led to a reduced or abrogated tumorigenicity in several different tumor models [49]. IL-2 also induces G2 cell cycle arrest via the Akt pathway [30]. However, other studies have suggested that IL-2 therapy may stimulate tumor cell growth. For example, a short 2-day treatment of low-dose IL-2 resulted in a decrease in tumor load and an increase in survival, whereas the longer administration of IL-2 promoted CD8 T cell growth [50]. Also, the addition of IL-2 to cyclophosphamide therapy reversed the growth inhibitory effects of cyclophosphamide on B16 melanoma cells and decreased survival time, compared with treatment with cyclophosphamide alone [51]. Therefore, IL-2 may have concentration/time-dependent effects on tumor growth and cytotoxicity.

The gene CYP19 expression was significantly increased by PEITC exposure. We confirmed the upregulation of CYP19 observed in the gene array studies, using RTQ RT-PCR. After normalization to actin, the increase of CYP19 was 1.8-fold compared to controls ( ) by RTQ RT-PCR, compared to 5.22-fold from the gene array data. The AP-1 motif, which regulates the CYP19 promoter [52], may be involved in the CYP19 induction, because 5–10  M PEITC has been reported to activate AP-1 activity in both prostate and bladder cancer cell lines [53, 54].

The induction of CYP19 (aromatase) which is a key enzyme involved in the conversion of androgens to estrogens, would be considered a negative effect with regards to cancer prevention [55]. Since estrogen causes cellular proliferation and some estrogen metabolites are considered carcinogens, local expression of aromatase has been correlated with tumor initiation and progression [55]. However, the significance of these results is unknown at this time since it is not known if increased transcription of the aromatase gene results in increased activity. Further studies concerning the effect of PEITC on CYP19 enzyme activity are needed.

5. Conclusions

In conclusion, PEITC treatment (3  M) can produce significant alterations in genes involved in tumor suppression and cellular proliferation/apoptosis. We report for the first time transcriptional induction of p53, ATF-2, hsp27, BRCA2, IL-2, p57, and CYP19 by PEITC in the human breast cancer cells, and our results are supported by other studies which have reported increased expression [33] and increased activity [38] of p53 protein and activation of Hsp27 [41]. These alterations in gene expression may be important in the mechanism of action of PEITC, especially for its chemopreventive effects. Further study is needed to capture some of the early response genes. In addition, the overall effect elicited by beneficial and adverse transcriptional changes needs to be considered. The present study may be useful as a first step in understanding the mechanisms underlying the breast cancer preventive activities of PEITC.


PEITC:Phenethyl Isothiocyanate
DMSO:Dimethyl sulfoxide
MMLV:Moloney murine leukemia virus
CYP:Cytochrome P450
MAPK:Mitogen-activated protein kinase


This paper was supported in part by a Grant from the Susan G. Komen Breast Cancer Foundation and from the National Institutes of Health CA121404. The authors thank Paul Saunders for his technical assistance.


  1. G. R. Fenwick, R. K. Heaney, and W. J. Mullin, “Glucosinolates and their breakdown products in food and food plants,” Critical Reviews in Food Science and Nutrition, vol. 18, no. 2, pp. 123–201, 1983. View at: Google Scholar
  2. S. M. Getahun and F.-L. Chung, “Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress,” Cancer Epidemiology Biomarkers and Prevention, vol. 8, no. 5, pp. 447–451, 1999. View at: Google Scholar
  3. S. S. Hecht, “Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism,” Journal of Nutrition, vol. 129, no. 3, pp. 768S–774S, 1999. View at: Google Scholar
  4. E. Bresnick, D. F. Birt, K. Wolterman, M. Wheeler, and R. S. Markin, “Reduction in mammary tumorigenesis in the rat by cabbage and cabbage residue,” Carcinogenesis, vol. 11, no. 7, pp. 1159–1163, 1990. View at: Google Scholar
  5. G. S. Stoewsand, J. L. Anderson, and L. Munson, “Protective effect of dietary brussels sprouts against mammary carcinogenesis in Sprague-Dawley rats,” Cancer Letters, vol. 39, no. 2, pp. 199–207, 1988. View at: Google Scholar
  6. L. W. Wattenberg, “Inhibition of carcinogen-induced neoplasia by sodium cyanate, tert-butyl isocyanate, and benzyl isothiocyanate administered subsequent to carcinogen exposure,” Cancer Research, vol. 41, no. 8, pp. 2991–2994, 1981. View at: Google Scholar
  7. J. H. Fowke, F.-L. Chung, F. Jin et al., “Urinary isothiocyanate levels, brassica, and human breast cancer,” Cancer Research, vol. 63, no. 14, pp. 3980–3986, 2003. View at: Google Scholar
  8. J. H. Fowke, C. Longcope, and J. R. Hebert, “Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 8, pp. 773–779, 2000. View at: Google Scholar
  9. S. S. Hecht, “Chemoprevention by isothiocyanates,” Journal of Cellular Biochemistry. Supplement, vol. 58, no. 22, pp. 195–209, 1995. View at: Google Scholar
  10. Y. Zhang and P. Talalay, “Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms,” Cancer Research, vol. 54, no. 7, pp. 1976s–1981s, 1994. View at: Google Scholar
  11. Z. Guo, T. J. Smith, E. Wang et al., “Effects of phenethyl isothiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats,” Carcinogenesis, vol. 13, no. 12, pp. 2205–2210, 1992. View at: Google Scholar
  12. U. Telang, D. A. Brazeau, and M. E. Morris, “Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells,” Experimental Biology and Medicine, vol. 234, no. 3, pp. 287–295, 2009. View at: Publisher Site | Google Scholar
  13. J. Antoslewicz, W. Ziolkowski, S. Kar, A. A. Powolny, and S. V. Singh, “Role of reactive oxygen intermediates in cellular responses to dietary cancer chemopreventive agents,” Planta Medica, vol. 74, no. 13, pp. 1570–1579, 2008. View at: Publisher Site | Google Scholar
  14. J. Jakubikova, Y. Bao, and J. Sedlak, “Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines,” Anticancer Research, vol. 25, no. 5, pp. 3375–3386, 2005. View at: Google Scholar
  15. R. Hu, B. R. Kim, C. Chen, V. Hebbar, and A.-N. T. Kong, “The roles of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cells,” Carcinogenesis, vol. 24, no. 8, pp. 1361–1367, 2003. View at: Publisher Site | Google Scholar
  16. E. Tseng, E. A. Scott-Ramsay, and M. E. Morris, “Dietary organic isothiocyanates are cytotoxic in human breast cancer MCF-7 and mammary epithelial MCF-12A cell lines,” Experimental Biology and Medicine, vol. 229, no. 8, pp. 835–842, 2004. View at: Google Scholar
  17. L. Kang and Z.-Y. Wang, “Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-α36,” Journal of Cellular and Molecular Medicine, vol. 14, no. 6B, pp. 1485–1493, 2010. View at: Publisher Site | Google Scholar
  18. X.-J. Wu and X. Hua, “Targeting ROS: selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound,” Cancer Biology and Therapy, vol. 6, no. 5, pp. 646–647, 2007. View at: Google Scholar
  19. X.-H. Wang, B. E. Cavell, S. S. Syed Alwi, and G. Packham, “Inhibition of hypoxia inducible factor by phenethyl isothiocyanate,” Biochemical Pharmacology, vol. 78, no. 3, pp. 261–272, 2009. View at: Publisher Site | Google Scholar
  20. K. Xu and P. J. Thornalley, “Studies on the mechanism of the inhibition of human leukaemia cell growth by dietary isothiocyanates and their cysteine adducts in vitro,” Biochemical Pharmacology, vol. 60, no. 2, pp. 221–231, 2000. View at: Publisher Site | Google Scholar
  21. L. B. von Weymarn, J. A. Chun, and P. F. Hollenberg, “Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers,” Carcinogenesis, vol. 27, no. 4, pp. 782–790, 2006. View at: Publisher Site | Google Scholar
  22. R. Yu, S. Mandlekar, K. J. Harvey, D. S. Ucker, and A.-N. T. Kong, “Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity,” Cancer Research, vol. 58, no. 3, pp. 402–408, 1998. View at: Google Scholar
  23. A. Nishikawa, F. Furukawa, I.-S. Lee, T. Tanaka, and M. Hirose, “Potent chemopreventive agents against pancreatic cancer,” Current Cancer Drug Targets, vol. 4, no. 4, pp. 373–384, 2004. View at: Publisher Site | Google Scholar
  24. C. Xu, G. Shen, C. Chen, C. Gélinas, and A.-N. T. Kong, “Suppression of NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through IκBα, IKK pathway in human prostate cancer PC-3 cells,” Oncogene, vol. 24, no. 28, pp. 4486–4495, 2005. View at: Publisher Site | Google Scholar
  25. Y. Ji and M. E. Morris, “Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry,” Analytical Biochemistry, vol. 323, no. 1, pp. 39–47, 2003. View at: Publisher Site | Google Scholar
  26. P. De Cremoux, C. Tran-Perennou, B. L. Brockdorff et al., “Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens,” Endocrine-Related Cancer, vol. 10, no. 3, pp. 409–418, 2003. View at: Publisher Site | Google Scholar
  27. C. Schäfer, P. Clapp, M. J. Welsh, R. Benndorf, and J. A. Williams, “HSP27 expression regulates CCK-induced changes of the actin cytoskeleton in CHO-CCK-A cells,” American Journal of Physiology, vol. 277, no. 6, pp. C1032–C1043, 1999. View at: Google Scholar
  28. S. L. Harris and A. J. Levine, “The p53 pathway: positive and negative feedback loops,” Oncogene, vol. 24, no. 17, pp. 2899–2908, 2005. View at: Publisher Site | Google Scholar
  29. C. Gao, Z. Zou, L. Xu, J. Moul, P. Seth, and S. Srivastava, “p53-dependent induction of heat shock protein 27 (hsp27) expression,” International Journal of Cancer, vol. 88, no. 2, pp. 191–194, 2000. View at: Publisher Site | Google Scholar
  30. R. Kibe, S. Zvonic, T. Iwakuma, S. K. Durum, and Y. Cui, “P53-dependent and -independent components of IL-2 mediated radioprotection in IL-2 dependent T cell lines,” The FASEB Journal, vol. 22, 2008, abstract no. 1070.31. View at: Google Scholar
  31. K. J. Patel, V. P. C. C. Yu, H. Lee et al., “Involvement of Brca2 in DNA repair,” Molecular Cell, vol. 1, no. 3, pp. 347–357, 1998. View at: Google Scholar
  32. A. M. Oliveira, J. S. Ross, and J. A. Fletcher, “Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers,” American Journal of Clinical Pathology, vol. 124, supplement, pp. S16–S28, 2005. View at: Google Scholar
  33. Y.-F. Kuang and Y.-H. Chen, “Induction of apoptosis in a non-small cell human lung cancer cell line by isothiocyanates is associated with P53 and P21,” Food and Chemical Toxicology, vol. 42, no. 10, pp. 1711–1718, 2004. View at: Publisher Site | Google Scholar
  34. Y.-R. Chen, W. Wang, A.-N. T. Kong, and T.-H. Tan, “Molecular mechanisms of c-jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates,” Journal of Biological Chemistry, vol. 273, no. 3, pp. 1769–1775, 1998. View at: Publisher Site | Google Scholar
  35. J. W. Lee and M. K. Cho, “Phenethyl isothiocyanate induced apoptosis via down regulation of Bcl-2/XIAP and triggering of the mitochondrial pathway in MCF-7 cells,” Archives of Pharmacal Research, vol. 31, no. 12, pp. 1604–1612, 2008. View at: Publisher Site | Google Scholar
  36. A. Powolny, K. Takahashi, R. G. Hopkins, and G. Loo, “Induction of GADD gene expression by phenethylisothiocyanate in human colon adenocarcinoma cells,” Journal of Cellular Biochemistry, vol. 90, no. 6, pp. 1128–1139, 2003. View at: Publisher Site | Google Scholar
  37. A. Yagi, Y. Hasegawa, H. Xiao et al., “GADD34 induces p53 phosphorylation and p21/WAF1 transcription,” Journal of Cellular Biochemistry, vol. 90, no. 6, pp. 1242–1249, 2003. View at: Publisher Site | Google Scholar
  38. Lombardi, Georgetown University Medical Center, 2009, http://www.eurekalert.org/pub_releases/2009-04/gumc-cis041809.php.
  39. I. S. Woo, T. Kohno, K. Inoue, S. Ishii, and J. Yokota, “Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer,” International Journal of Oncology, vol. 20, no. 3, pp. 527–531, 2002. View at: Google Scholar
  40. A.-N. T. Kong, E. Owuor, R. Yu et al., “Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE),” Drug Metabolism Reviews, vol. 33, no. 3-4, pp. 255–271, 2001. View at: Publisher Site | Google Scholar
  41. J. C. H. Neo, P. Rose, C. N. Ong, and M. C. M. Chung, “β-phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes,” Proteomics, vol. 5, no. 4, pp. 1075–1082, 2005. View at: Publisher Site | Google Scholar
  42. G. Dimri, H. Band, and V. Band, “Mammary epithelial cell transformation: insights from cell culture and mouse models,” Breast Cancer Research, vol. 7, no. 4, pp. 171–179, 2005. View at: Publisher Site | Google Scholar
  43. S.-J. Suh, S.-K. Moon, and C.-H. Kim, “Raphanus sativus and its isothiocyanates inhibit vascular smooth muscle cells proliferation and induce G1 cell cycle arrest,” International Immunopharmacology, vol. 6, no. 5, pp. 854–861, 2006. View at: Publisher Site | Google Scholar
  44. J. W. Chiao, H. Wu, G. Ramaswamy et al., “Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest,” Carcinogenesis, vol. 25, no. 8, pp. 1403–1408, 2004. View at: Publisher Site | Google Scholar
  45. K. L. Cheung, T. O. Khor, S. Yu, and A.-N. T. Kong, “PEITC induces G1 cell cycle arrest on HT-29 cells through the activation of p38 MAPK signaling pathway,” AAPS Journal, vol. 10, no. 2, pp. 277–281, 2008. View at: Publisher Site | Google Scholar
  46. S. Matsuoka, M. C. Edwards, C. Bai et al., “p57(KIP2), a structurally distinct member of the p21(CIP1) Cdk inhibitor family, is a candidate tumor suppressor gene,” Genes and Development, vol. 9, no. 6, pp. 650–662, 1995. View at: Google Scholar
  47. J. Kotsopoulos and S. A. Narod, “Towards a dietary prevention of hereditary breast cancer,” Cancer Causes and Control, vol. 16, no. 2, pp. 125–138, 2005. View at: Publisher Site | Google Scholar
  48. C. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma,” Anti-Cancer Drugs, vol. 17, no. 1, pp. 1–12, 2006. View at: Publisher Site | Google Scholar
  49. R. Foa, A. Guarini, and B. Gansbacher, “IL2 treatment for cancer: from biology to gene therapy,” British Journal of Cancer, vol. 66, no. 6, pp. 992–998, 1992. View at: Google Scholar
  50. P. Shrikant and M. F. Mescher, “Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis,” Journal of Immunology, vol. 169, no. 4, pp. 1753–1759, 2002. View at: Google Scholar
  51. T. Palomares, A. Alonso-Varona, A. Alvarez, B. Castro, Y. Calle, and P. Bilbao, “Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells,” Clinical and Experimental Metastasis, vol. 15, no. 3, pp. 329–337, 1997. View at: Publisher Site | Google Scholar
  52. S. Catalano, S. Marsico, C. Giordano et al., “Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line,” Journal of Biological Chemistry, vol. 278, no. 31, pp. 28668–28676, 2003. View at: Publisher Site | Google Scholar
  53. C. Xu, G. Shen, X. Yuan et al., “ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells,” Carcinogenesis, vol. 27, no. 3, pp. 437–445, 2006. View at: Publisher Site | Google Scholar
  54. J. Li, S. Yao, and Y. Zhang, “The role of c-Jun in the AP-1 activation induced by naturally occurring isothiocyanates,” Food and Chemical Toxicology, vol. 43, no. 9, pp. 1373–1380, 2005. View at: Publisher Site | Google Scholar
  55. R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz, “Aromatase inhibitors in the treatment of breast cancer,” Endocrine Reviews, vol. 26, no. 3, pp. 331–345, 2005. View at: Publisher Site | Google Scholar

Copyright © 2011 Young Jin Moon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.